| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 498 | 2024 | 4818 | 30.200 |
Why?
|
| Antidepressive Agents | 266 | 2024 | 2913 | 20.620 |
Why?
|
| Fluoxetine | 119 | 2012 | 733 | 11.330 |
Why?
|
| Depressive Disorder | 164 | 2024 | 3721 | 9.830 |
Why?
|
| Citalopram | 82 | 2019 | 401 | 8.180 |
Why?
|
| Antidepressive Agents, Second-Generation | 76 | 2021 | 491 | 7.720 |
Why?
|
| Psychiatric Status Rating Scales | 213 | 2024 | 6029 | 5.570 |
Why?
|
| Depression | 111 | 2024 | 8230 | 4.980 |
Why?
|
| Ketamine | 21 | 2022 | 527 | 4.680 |
Why?
|
| Double-Blind Method | 189 | 2024 | 12465 | 4.300 |
Why?
|
| Sertraline | 36 | 2024 | 209 | 3.900 |
Why?
|
| Thiophenes | 18 | 2017 | 570 | 3.870 |
Why?
|
| Piperazines | 37 | 2020 | 2554 | 3.730 |
Why?
|
| Anger | 36 | 2020 | 405 | 3.660 |
Why?
|
| Antipsychotic Agents | 39 | 2023 | 3081 | 3.620 |
Why?
|
| Drug Therapy, Combination | 111 | 2024 | 6316 | 3.620 |
Why?
|
| S-Adenosylmethionine | 21 | 2019 | 219 | 3.400 |
Why?
|
| Placebo Effect | 18 | 2024 | 517 | 3.200 |
Why?
|
| Quinolones | 15 | 2017 | 389 | 3.140 |
Why?
|
| Bupropion | 36 | 2022 | 303 | 3.060 |
Why?
|
| Treatment Outcome | 317 | 2024 | 65371 | 2.990 |
Why?
|
| Personality Inventory | 76 | 2019 | 1018 | 2.950 |
Why?
|
| Placebos | 26 | 2019 | 1667 | 2.480 |
Why?
|
| Anxiety Disorders | 44 | 2022 | 2748 | 2.400 |
Why?
|
| Adult | 567 | 2024 | 223646 | 2.330 |
Why?
|
| Folic Acid | 19 | 2016 | 1337 | 2.150 |
Why?
|
| Paroxetine | 16 | 2023 | 181 | 2.100 |
Why?
|
| Somatoform Disorders | 19 | 2008 | 425 | 2.070 |
Why?
|
| Middle Aged | 477 | 2024 | 223492 | 2.050 |
Why?
|
| Suicidal Ideation | 31 | 2023 | 1462 | 2.030 |
Why?
|
| Personality Disorders | 25 | 2009 | 726 | 2.010 |
Why?
|
| Suicide, Attempted | 30 | 2022 | 1409 | 1.980 |
Why?
|
| Drug Resistance | 43 | 2017 | 1599 | 1.960 |
Why?
|
| Humans | 851 | 2024 | 768166 | 1.950 |
Why?
|
| Ambulatory Care | 68 | 2017 | 2783 | 1.940 |
Why?
|
| Naltrexone | 5 | 2019 | 319 | 1.930 |
Why?
|
| Male | 589 | 2024 | 364719 | 1.910 |
Why?
|
| Female | 614 | 2024 | 397192 | 1.880 |
Why?
|
| Buspirone | 10 | 2015 | 80 | 1.790 |
Why?
|
| Antidepressive Agents, Tricyclic | 23 | 2014 | 430 | 1.770 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 52 | 2021 | 1988 | 1.740 |
Why?
|
| Irritable Mood | 9 | 2020 | 196 | 1.710 |
Why?
|
| Fatigue | 18 | 2016 | 1557 | 1.680 |
Why?
|
| Anxiety | 38 | 2022 | 4672 | 1.670 |
Why?
|
| Dose-Response Relationship, Drug | 75 | 2022 | 10760 | 1.660 |
Why?
|
| Randomized Controlled Trials as Topic | 58 | 2023 | 10399 | 1.640 |
Why?
|
| Cyclohexanols | 23 | 2012 | 126 | 1.640 |
Why?
|
| Severity of Illness Index | 105 | 2020 | 15948 | 1.530 |
Why?
|
| Bipolar Disorder | 27 | 2022 | 5130 | 1.500 |
Why?
|
| Hypericum | 11 | 2014 | 58 | 1.440 |
Why?
|
| Homocysteine | 10 | 2012 | 637 | 1.390 |
Why?
|
| Aminopyridines | 3 | 2020 | 580 | 1.390 |
Why?
|
| Adrenergic Uptake Inhibitors | 6 | 2020 | 186 | 1.390 |
Why?
|
| Adolescent | 230 | 2024 | 89169 | 1.350 |
Why?
|
| Research Design | 28 | 2023 | 6211 | 1.350 |
Why?
|
| Primary Health Care | 30 | 2024 | 4746 | 1.340 |
Why?
|
| Serotonin Receptor Agonists | 6 | 2015 | 151 | 1.320 |
Why?
|
| Comorbidity | 88 | 2018 | 10590 | 1.290 |
Why?
|
| Mianserin | 11 | 2012 | 51 | 1.280 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 15 | 2013 | 1107 | 1.220 |
Why?
|
| Vitamin B 12 | 8 | 2012 | 529 | 1.220 |
Why?
|
| Urea | 6 | 2021 | 448 | 1.210 |
Why?
|
| Clinical Trials as Topic | 33 | 2020 | 8054 | 1.180 |
Why?
|
| Cognition Disorders | 11 | 2018 | 3980 | 1.140 |
Why?
|
| Tetrahydrofolates | 5 | 2016 | 58 | 1.090 |
Why?
|
| Drug Administration Schedule | 52 | 2019 | 4860 | 1.070 |
Why?
|
| Psychometrics | 38 | 2018 | 3063 | 1.060 |
Why?
|
| Young Adult | 140 | 2024 | 60066 | 1.030 |
Why?
|
| Buprenorphine | 4 | 2019 | 667 | 1.010 |
Why?
|
| Aged | 225 | 2024 | 171504 | 0.990 |
Why?
|
| Mood Disorders | 9 | 2015 | 1129 | 0.970 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 11 | 2022 | 3729 | 0.960 |
Why?
|
| Delayed-Action Preparations | 24 | 2022 | 969 | 0.950 |
Why?
|
| Thiazoles | 9 | 2018 | 1542 | 0.940 |
Why?
|
| Psychopharmacology | 5 | 2019 | 146 | 0.940 |
Why?
|
| Hostility | 15 | 2015 | 185 | 0.930 |
Why?
|
| Risperidone | 4 | 2021 | 383 | 0.930 |
Why?
|
| Pyrrolidines | 2 | 2020 | 340 | 0.920 |
Why?
|
| Narcotic Antagonists | 3 | 2020 | 591 | 0.910 |
Why?
|
| Suicide | 25 | 2024 | 1606 | 0.870 |
Why?
|
| Nortriptyline | 7 | 2014 | 79 | 0.870 |
Why?
|
| Brain | 45 | 2024 | 27360 | 0.870 |
Why?
|
| Central Nervous System Stimulants | 8 | 2022 | 1168 | 0.860 |
Why?
|
| Interview, Psychological | 9 | 2017 | 810 | 0.860 |
Why?
|
| Anti-Anxiety Agents | 6 | 2013 | 405 | 0.850 |
Why?
|
| Students | 12 | 2021 | 1744 | 0.850 |
Why?
|
| Reward | 12 | 2021 | 981 | 0.840 |
Why?
|
| Nicotinic Agonists | 4 | 2018 | 265 | 0.840 |
Why?
|
| Panic Disorder | 12 | 2020 | 613 | 0.840 |
Why?
|
| Norepinephrine | 5 | 2020 | 898 | 0.840 |
Why?
|
| Piperidines | 7 | 2021 | 1667 | 0.830 |
Why?
|
| Dopamine Uptake Inhibitors | 5 | 2009 | 287 | 0.830 |
Why?
|
| Emotions | 13 | 2023 | 2767 | 0.820 |
Why?
|
| Phytotherapy | 8 | 2013 | 298 | 0.780 |
Why?
|
| Electroconvulsive Therapy | 8 | 2024 | 505 | 0.760 |
Why?
|
| Triiodothyronine | 8 | 2014 | 492 | 0.750 |
Why?
|
| Combined Modality Therapy | 23 | 2024 | 8542 | 0.750 |
Why?
|
| Republic of Korea | 23 | 2022 | 591 | 0.740 |
Why?
|
| Viloxazine | 4 | 2022 | 14 | 0.740 |
Why?
|
| Hypnotics and Sedatives | 7 | 2022 | 1191 | 0.730 |
Why?
|
| Patient Dropouts | 17 | 2012 | 411 | 0.730 |
Why?
|
| Yoga | 5 | 2024 | 280 | 0.730 |
Why?
|
| Galantamine | 2 | 2013 | 33 | 0.720 |
Why?
|
| Tobacco Use Disorder | 8 | 2017 | 708 | 0.720 |
Why?
|
| Motivation | 8 | 2017 | 2020 | 0.710 |
Why?
|
| Models, Statistical | 8 | 2019 | 5107 | 0.710 |
Why?
|
| Neurogenesis | 2 | 2020 | 864 | 0.700 |
Why?
|
| Nucleus Accumbens | 2 | 2015 | 358 | 0.690 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2024 | 136 | 0.680 |
Why?
|
| Electroencephalography | 14 | 2024 | 6314 | 0.670 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 3 | 2021 | 25 | 0.660 |
Why?
|
| Tachyphylaxis | 2 | 2018 | 54 | 0.650 |
Why?
|
| Morpholines | 3 | 2017 | 584 | 0.650 |
Why?
|
| Psychotic Disorders | 12 | 2022 | 3276 | 0.640 |
Why?
|
| Excitatory Amino Acid Antagonists | 4 | 2023 | 451 | 0.640 |
Why?
|
| Remission Induction | 19 | 2016 | 2410 | 0.630 |
Why?
|
| Melatonin | 3 | 2016 | 670 | 0.630 |
Why?
|
| Triazoles | 5 | 2010 | 904 | 0.630 |
Why?
|
| Desipramine | 9 | 2004 | 183 | 0.630 |
Why?
|
| Neuropsychological Tests | 12 | 2018 | 7140 | 0.620 |
Why?
|
| Tai Ji | 3 | 2017 | 291 | 0.620 |
Why?
|
| Monoamine Oxidase Inhibitors | 9 | 2006 | 153 | 0.610 |
Why?
|
| Factor Analysis, Statistical | 8 | 2014 | 1001 | 0.610 |
Why?
|
| Schizophrenia | 12 | 2021 | 6983 | 0.600 |
Why?
|
| Mental Health Services | 9 | 2014 | 1732 | 0.600 |
Why?
|
| Sexual Dysfunctions, Psychological | 7 | 2018 | 193 | 0.590 |
Why?
|
| Thinking | 3 | 2021 | 320 | 0.590 |
Why?
|
| Outpatients | 23 | 2020 | 1600 | 0.580 |
Why?
|
| Magnetic Field Therapy | 1 | 2017 | 27 | 0.570 |
Why?
|
| Substance Withdrawal Syndrome | 8 | 2018 | 628 | 0.570 |
Why?
|
| Psychotherapy | 14 | 2024 | 1654 | 0.570 |
Why?
|
| Phenylethyl Alcohol | 1 | 2017 | 13 | 0.570 |
Why?
|
| Prolactin | 6 | 2013 | 627 | 0.570 |
Why?
|
| Child of Impaired Parents | 6 | 2011 | 462 | 0.560 |
Why?
|
| Infusions, Intravenous | 10 | 2022 | 2230 | 0.560 |
Why?
|
| Serotonin Agents | 1 | 2016 | 29 | 0.550 |
Why?
|
| Weight Gain | 12 | 2023 | 2359 | 0.550 |
Why?
|
| Stress, Psychological | 16 | 2021 | 4530 | 0.550 |
Why?
|
| Fatty Acids, Omega-3 | 8 | 2023 | 1399 | 0.550 |
Why?
|
| Sick Role | 5 | 2004 | 229 | 0.550 |
Why?
|
| Disorders of Excessive Somnolence | 5 | 2009 | 279 | 0.540 |
Why?
|
| Emigrants and Immigrants | 7 | 2016 | 550 | 0.540 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2018 | 228 | 0.530 |
Why?
|
| Cognition | 14 | 2023 | 7073 | 0.530 |
Why?
|
| Bulimia | 6 | 2018 | 405 | 0.530 |
Why?
|
| Serotonin | 7 | 2023 | 1043 | 0.530 |
Why?
|
| Eicosapentaenoic Acid | 5 | 2023 | 565 | 0.520 |
Why?
|
| Premenopause | 2 | 2019 | 1039 | 0.520 |
Why?
|
| Recurrence | 36 | 2019 | 8509 | 0.520 |
Why?
|
| Analgesics, Opioid | 3 | 2018 | 3837 | 0.510 |
Why?
|
| Prevalence | 41 | 2024 | 15869 | 0.510 |
Why?
|
| Apathy | 2 | 2014 | 107 | 0.510 |
Why?
|
| Scopolamine | 1 | 2016 | 93 | 0.510 |
Why?
|
| Health Status | 10 | 2013 | 4091 | 0.510 |
Why?
|
| Multicenter Studies as Topic | 14 | 2017 | 1737 | 0.510 |
Why?
|
| Cholesterol | 6 | 2004 | 2914 | 0.500 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2017 | 265 | 0.500 |
Why?
|
| Arousal | 10 | 2024 | 1180 | 0.500 |
Why?
|
| Universities | 10 | 2019 | 1005 | 0.500 |
Why?
|
| Folic Acid Deficiency | 6 | 2009 | 117 | 0.500 |
Why?
|
| Clonazepam | 5 | 2010 | 135 | 0.490 |
Why?
|
| S-Adenosylhomocysteine | 2 | 2014 | 40 | 0.490 |
Why?
|
| Models, Psychological | 4 | 2015 | 825 | 0.490 |
Why?
|
| Lithium | 8 | 2006 | 600 | 0.490 |
Why?
|
| Drug Partial Agonism | 1 | 2015 | 24 | 0.490 |
Why?
|
| Cultural Competency | 3 | 2018 | 303 | 0.490 |
Why?
|
| Child Behavior Disorders | 5 | 2011 | 812 | 0.490 |
Why?
|
| Patient Selection | 10 | 2017 | 4260 | 0.490 |
Why?
|
| Hospitals, General | 6 | 2020 | 809 | 0.490 |
Why?
|
| Pilot Projects | 25 | 2020 | 8741 | 0.480 |
Why?
|
| Transcranial Magnetic Stimulation | 3 | 2024 | 1490 | 0.480 |
Why?
|
| Frontal Lobe | 6 | 2022 | 1426 | 0.480 |
Why?
|
| Telemedicine | 6 | 2020 | 3109 | 0.480 |
Why?
|
| Obsessive-Compulsive Disorder | 7 | 2017 | 1508 | 0.470 |
Why?
|
| Complementary Therapies | 5 | 2010 | 487 | 0.470 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 640 | 0.470 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2013 | 330 | 0.470 |
Why?
|
| Psychotherapy, Group | 2 | 2009 | 417 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 44 | 2024 | 36743 | 0.470 |
Why?
|
| Smoking Cessation | 6 | 2014 | 2085 | 0.460 |
Why?
|
| Time Factors | 45 | 2024 | 40218 | 0.460 |
Why?
|
| Behavior, Addictive | 6 | 2021 | 428 | 0.460 |
Why?
|
| Receptors, Opioid, mu | 1 | 2015 | 171 | 0.460 |
Why?
|
| Benzhydryl Compounds | 6 | 2016 | 944 | 0.460 |
Why?
|
| Receptors, Nicotinic | 2 | 2015 | 494 | 0.450 |
Why?
|
| Benzamides | 1 | 2020 | 1379 | 0.450 |
Why?
|
| Drug Synergism | 10 | 2017 | 1760 | 0.450 |
Why?
|
| Follow-Up Studies | 48 | 2020 | 39348 | 0.450 |
Why?
|
| Hydrocortisone | 10 | 2020 | 1841 | 0.440 |
Why?
|
| Amnesia, Anterograde | 1 | 2013 | 20 | 0.440 |
Why?
|
| Imipramine | 3 | 2006 | 98 | 0.440 |
Why?
|
| Psychotherapy, Brief | 1 | 2014 | 118 | 0.440 |
Why?
|
| Compulsive Behavior | 4 | 2021 | 117 | 0.440 |
Why?
|
| Azabicyclo Compounds | 3 | 2010 | 68 | 0.430 |
Why?
|
| Sexual Dysfunction, Physiological | 6 | 2020 | 364 | 0.430 |
Why?
|
| Aldehydes | 1 | 2014 | 170 | 0.430 |
Why?
|
| Panic | 4 | 2019 | 103 | 0.430 |
Why?
|
| Pharmacogenetics | 4 | 2020 | 683 | 0.430 |
Why?
|
| Heterocyclic Compounds | 1 | 2014 | 245 | 0.420 |
Why?
|
| Central Nervous System Agents | 1 | 2013 | 73 | 0.420 |
Why?
|
| Mental Disorders | 20 | 2018 | 6874 | 0.410 |
Why?
|
| Akathisia, Drug-Induced | 5 | 2017 | 66 | 0.410 |
Why?
|
| Caudate Nucleus | 4 | 2009 | 391 | 0.410 |
Why?
|
| Adrenergic Agents | 1 | 2013 | 72 | 0.410 |
Why?
|
| Risk Factors | 70 | 2023 | 74944 | 0.410 |
Why?
|
| Psychological Tests | 5 | 2012 | 643 | 0.410 |
Why?
|
| Age of Onset | 21 | 2011 | 3347 | 0.410 |
Why?
|
| Hyperprolactinemia | 4 | 2010 | 124 | 0.410 |
Why?
|
| Phobic Disorders | 9 | 2011 | 441 | 0.410 |
Why?
|
| Riluzole | 3 | 2019 | 62 | 0.410 |
Why?
|
| Resilience, Psychological | 4 | 2021 | 807 | 0.400 |
Why?
|
| Leptin | 4 | 2019 | 1599 | 0.400 |
Why?
|
| Nootropic Agents | 1 | 2013 | 159 | 0.400 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2013 | 187 | 0.400 |
Why?
|
| Prospective Studies | 55 | 2023 | 54926 | 0.400 |
Why?
|
| Fentanyl | 1 | 2015 | 451 | 0.390 |
Why?
|
| Plant Preparations | 3 | 2011 | 94 | 0.390 |
Why?
|
| Sex Characteristics | 4 | 2019 | 2650 | 0.390 |
Why?
|
| Culture | 5 | 2014 | 622 | 0.390 |
Why?
|
| Social Adjustment | 7 | 2011 | 635 | 0.390 |
Why?
|
| Trazodone | 3 | 2007 | 67 | 0.390 |
Why?
|
| Postmenopause | 3 | 2020 | 2518 | 0.390 |
Why?
|
| Aza Compounds | 1 | 2011 | 34 | 0.380 |
Why?
|
| Psychiatry | 8 | 2011 | 1716 | 0.380 |
Why?
|
| Reproducibility of Results | 31 | 2020 | 20227 | 0.380 |
Why?
|
| Quality of Life | 24 | 2023 | 13490 | 0.380 |
Why?
|
| Fluvoxamine | 4 | 2010 | 78 | 0.380 |
Why?
|
| Aggression | 8 | 2008 | 750 | 0.380 |
Why?
|
| Polymorphism, Genetic | 5 | 2012 | 4249 | 0.370 |
Why?
|
| Amygdala | 6 | 2019 | 1380 | 0.370 |
Why?
|
| Alcohol-Related Disorders | 2 | 2010 | 243 | 0.370 |
Why?
|
| Temperament | 2 | 2012 | 301 | 0.370 |
Why?
|
| Nicotine | 4 | 2018 | 680 | 0.370 |
Why?
|
| Single-Blind Method | 14 | 2020 | 1587 | 0.370 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2012 | 276 | 0.360 |
Why?
|
| Acupuncture Therapy | 4 | 2012 | 486 | 0.360 |
Why?
|
| Glycine | 2 | 2011 | 672 | 0.360 |
Why?
|
| Probability | 10 | 2021 | 2479 | 0.360 |
Why?
|
| Mass Screening | 10 | 2024 | 5458 | 0.360 |
Why?
|
| Regression Analysis | 17 | 2019 | 6340 | 0.360 |
Why?
|
| Tomography, Emission-Computed | 2 | 2004 | 1126 | 0.350 |
Why?
|
| Gyrus Cinguli | 7 | 2020 | 1135 | 0.350 |
Why?
|
| Cyclopropanes | 2 | 2016 | 436 | 0.350 |
Why?
|
| Research | 2 | 2018 | 1979 | 0.350 |
Why?
|
| Self Report | 16 | 2018 | 3773 | 0.350 |
Why?
|
| Pain | 7 | 2008 | 5100 | 0.350 |
Why?
|
| Delusions | 3 | 2022 | 300 | 0.340 |
Why?
|
| Psychotropic Drugs | 6 | 2017 | 881 | 0.340 |
Why?
|
| Patient Compliance | 6 | 2010 | 2697 | 0.340 |
Why?
|
| Sleep | 8 | 2017 | 4819 | 0.340 |
Why?
|
| Positron-Emission Tomography | 7 | 2024 | 6669 | 0.340 |
Why?
|
| Affect | 9 | 2021 | 1495 | 0.340 |
Why?
|
| Chronic Disease | 21 | 2020 | 9384 | 0.340 |
Why?
|
| Smoking | 13 | 2015 | 9092 | 0.330 |
Why?
|
| Self Concept | 4 | 2014 | 1043 | 0.330 |
Why?
|
| Intention | 1 | 2012 | 347 | 0.330 |
Why?
|
| Erectile Dysfunction | 5 | 2006 | 437 | 0.330 |
Why?
|
| Pregnanolone | 2 | 2020 | 67 | 0.330 |
Why?
|
| Hypochondriasis | 4 | 2016 | 93 | 0.330 |
Why?
|
| Cerebral Cortex | 9 | 2018 | 5812 | 0.330 |
Why?
|
| Affective Symptoms | 2 | 2012 | 418 | 0.330 |
Why?
|
| Pyridines | 3 | 2010 | 2894 | 0.330 |
Why?
|
| Reproduction | 1 | 2013 | 646 | 0.320 |
Why?
|
| Thyrotropin | 8 | 2014 | 834 | 0.320 |
Why?
|
| Obsessive Behavior | 2 | 2021 | 51 | 0.320 |
Why?
|
| Life Change Events | 6 | 2014 | 960 | 0.320 |
Why?
|
| Linear Models | 4 | 2020 | 5884 | 0.310 |
Why?
|
| Psychomotor Agitation | 3 | 2022 | 307 | 0.310 |
Why?
|
| Body Mass Index | 8 | 2020 | 13053 | 0.310 |
Why?
|
| Drug Discovery | 3 | 2019 | 1068 | 0.310 |
Why?
|
| Secondary Prevention | 11 | 2011 | 1474 | 0.300 |
Why?
|
| Brain-Derived Neurotrophic Factor | 4 | 2019 | 605 | 0.300 |
Why?
|
| Midazolam | 4 | 2022 | 267 | 0.300 |
Why?
|
| Demography | 13 | 2016 | 1641 | 0.300 |
Why?
|
| Benzodiazepines | 4 | 2022 | 1138 | 0.300 |
Why?
|
| Prefrontal Cortex | 6 | 2022 | 2238 | 0.300 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2022 | 903 | 0.290 |
Why?
|
| Bereavement | 4 | 2013 | 310 | 0.290 |
Why?
|
| Medication Adherence | 3 | 2014 | 2187 | 0.290 |
Why?
|
| Dietary Supplements | 6 | 2023 | 3445 | 0.290 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2014 | 3231 | 0.290 |
Why?
|
| Alzheimer Disease | 4 | 2023 | 8759 | 0.290 |
Why?
|
| Cooperative Behavior | 3 | 2012 | 1514 | 0.290 |
Why?
|
| Socioeconomic Factors | 15 | 2013 | 7852 | 0.290 |
Why?
|
| Dissociative Disorders | 3 | 2022 | 235 | 0.290 |
Why?
|
| Alcohol Drinking | 6 | 2012 | 4045 | 0.290 |
Why?
|
| Theta Rhythm | 3 | 2018 | 222 | 0.280 |
Why?
|
| Clinical Protocols | 7 | 2011 | 1443 | 0.280 |
Why?
|
| Cross-Cultural Comparison | 4 | 2016 | 638 | 0.280 |
Why?
|
| Antioxidants | 1 | 2015 | 1673 | 0.280 |
Why?
|
| Moclobemide | 1 | 2006 | 4 | 0.280 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2005 | 187 | 0.280 |
Why?
|
| C-Reactive Protein | 5 | 2023 | 3858 | 0.280 |
Why?
|
| Analysis of Variance | 14 | 2017 | 6229 | 0.280 |
Why?
|
| Treatment Failure | 13 | 2014 | 2661 | 0.270 |
Why?
|
| Receptors, Dopamine | 2 | 2002 | 293 | 0.270 |
Why?
|
| Behavior Therapy | 3 | 2009 | 886 | 0.270 |
Why?
|
| Social Behavior | 2 | 2011 | 1147 | 0.270 |
Why?
|
| Testosterone | 4 | 2020 | 2491 | 0.270 |
Why?
|
| Massachusetts | 15 | 2020 | 8890 | 0.270 |
Why?
|
| Mental Fatigue | 1 | 2006 | 23 | 0.270 |
Why?
|
| Estrogens | 1 | 2013 | 1536 | 0.270 |
Why?
|
| Substance-Related Disorders | 15 | 2020 | 4423 | 0.270 |
Why?
|
| Impulsive Behavior | 3 | 2019 | 345 | 0.270 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 1141 | 0.270 |
Why?
|
| Drug Therapy | 2 | 2007 | 504 | 0.270 |
Why?
|
| Self-Help Groups | 2 | 2020 | 194 | 0.260 |
Why?
|
| Interviews as Topic | 9 | 2014 | 2741 | 0.260 |
Why?
|
| Obesity | 8 | 2022 | 13090 | 0.260 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2006 | 56 | 0.260 |
Why?
|
| Aptitude | 1 | 2006 | 43 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 9 | 2016 | 3780 | 0.260 |
Why?
|
| Disease Management | 2 | 2016 | 2536 | 0.260 |
Why?
|
| Quinolines | 1 | 2011 | 772 | 0.260 |
Why?
|
| Alcoholism | 8 | 2019 | 1980 | 0.260 |
Why?
|
| Fear | 4 | 2019 | 1495 | 0.250 |
Why?
|
| Long-Term Care | 8 | 2016 | 631 | 0.250 |
Why?
|
| Chi-Square Distribution | 9 | 2009 | 3436 | 0.250 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 241 | 0.250 |
Why?
|
| Personality Assessment | 9 | 2015 | 646 | 0.250 |
Why?
|
| Docosahexaenoic Acids | 3 | 2023 | 914 | 0.250 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 624 | 0.250 |
Why?
|
| Adaptation, Psychological | 5 | 2021 | 2663 | 0.250 |
Why?
|
| Sex Factors | 23 | 2017 | 10632 | 0.250 |
Why?
|
| Juvenile Delinquency | 2 | 2003 | 116 | 0.250 |
Why?
|
| Choice Behavior | 3 | 2010 | 848 | 0.250 |
Why?
|
| Problem Solving | 2 | 2006 | 443 | 0.250 |
Why?
|
| Attitude | 6 | 2009 | 771 | 0.240 |
Why?
|
| Predictive Value of Tests | 14 | 2020 | 15454 | 0.240 |
Why?
|
| Thiazepines | 2 | 2015 | 30 | 0.240 |
Why?
|
| Anticonvulsants | 2 | 2010 | 1923 | 0.240 |
Why?
|
| Leucovorin | 2 | 2009 | 643 | 0.240 |
Why?
|
| Personality Development | 2 | 1996 | 241 | 0.240 |
Why?
|
| Cues | 4 | 2017 | 878 | 0.240 |
Why?
|
| Propylamines | 1 | 2005 | 161 | 0.230 |
Why?
|
| Depression, Postpartum | 2 | 2022 | 355 | 0.230 |
Why?
|
| Behavior, Animal | 1 | 2012 | 1862 | 0.230 |
Why?
|
| United States | 36 | 2024 | 73039 | 0.230 |
Why?
|
| Saliva | 1 | 2009 | 853 | 0.230 |
Why?
|
| Creatine | 3 | 2011 | 427 | 0.230 |
Why?
|
| Physical Fitness | 1 | 2009 | 744 | 0.230 |
Why?
|
| Logistic Models | 14 | 2015 | 13290 | 0.230 |
Why?
|
| Dopamine | 4 | 2024 | 1592 | 0.230 |
Why?
|
| Statistics as Topic | 6 | 2016 | 2357 | 0.230 |
Why?
|
| Fenfluramine | 2 | 2003 | 58 | 0.230 |
Why?
|
| Radioimmunoassay | 4 | 2009 | 863 | 0.230 |
Why?
|
| Administration, Intranasal | 3 | 2020 | 485 | 0.230 |
Why?
|
| Cross-Over Studies | 7 | 2022 | 2107 | 0.220 |
Why?
|
| Dopamine Agonists | 3 | 2013 | 347 | 0.220 |
Why?
|
| Pain Measurement | 6 | 2018 | 3583 | 0.220 |
Why?
|
| Age Factors | 20 | 2023 | 18412 | 0.220 |
Why?
|
| Cohort Studies | 26 | 2023 | 41754 | 0.220 |
Why?
|
| Wakefulness | 1 | 2010 | 1284 | 0.220 |
Why?
|
| Type A Personality | 4 | 1993 | 24 | 0.220 |
Why?
|
| Antimanic Agents | 6 | 2020 | 524 | 0.220 |
Why?
|
| Telomere | 3 | 2018 | 944 | 0.220 |
Why?
|
| Cross-Sectional Studies | 28 | 2021 | 26379 | 0.210 |
Why?
|
| Receptors, Serotonin | 2 | 2009 | 211 | 0.210 |
Why?
|
| China | 5 | 2017 | 2395 | 0.210 |
Why?
|
| Internet | 4 | 2020 | 3110 | 0.210 |
Why?
|
| Neural Pathways | 6 | 2019 | 3117 | 0.210 |
Why?
|
| Specialization | 1 | 2008 | 779 | 0.210 |
Why?
|
| Choline | 3 | 1999 | 522 | 0.210 |
Why?
|
| Dehydroepiandrosterone | 5 | 2001 | 259 | 0.210 |
Why?
|
| Feasibility Studies | 7 | 2017 | 5315 | 0.210 |
Why?
|
| 1-Naphthylamine | 3 | 1998 | 48 | 0.210 |
Why?
|
| Mental Status Schedule | 2 | 2012 | 315 | 0.210 |
Why?
|
| Metabolic Diseases | 1 | 2009 | 684 | 0.210 |
Why?
|
| Statistics, Nonparametric | 7 | 2012 | 2862 | 0.200 |
Why?
|
| Heart Rate | 4 | 2020 | 4214 | 0.200 |
Why?
|
| Drug Design | 1 | 2008 | 1046 | 0.200 |
Why?
|
| Tryptophan | 2 | 2002 | 482 | 0.200 |
Why?
|
| Emigration and Immigration | 2 | 2004 | 406 | 0.200 |
Why?
|
| Pirenzepine | 1 | 2002 | 116 | 0.200 |
Why?
|
| Basal Ganglia | 4 | 2001 | 553 | 0.200 |
Why?
|
| Androgens | 1 | 2009 | 1281 | 0.200 |
Why?
|
| Lithium Chloride | 1 | 2002 | 83 | 0.200 |
Why?
|
| Reaction Time | 5 | 2022 | 2101 | 0.200 |
Why?
|
| Memantine | 1 | 2023 | 111 | 0.200 |
Why?
|
| Sulfones | 5 | 2013 | 448 | 0.190 |
Why?
|
| Dysthymic Disorder | 2 | 2003 | 73 | 0.190 |
Why?
|
| Parkinson Disease | 3 | 2011 | 2893 | 0.190 |
Why?
|
| Terminology as Topic | 3 | 2006 | 1542 | 0.190 |
Why?
|
| Attitude to Health | 4 | 2013 | 2025 | 0.190 |
Why?
|
| Nursing Homes | 1 | 2009 | 1084 | 0.190 |
Why?
|
| Activities of Daily Living | 5 | 2016 | 2430 | 0.190 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2022 | 92 | 0.180 |
Why?
|
| Pituitary-Adrenal System | 4 | 2018 | 555 | 0.180 |
Why?
|
| Menopause | 3 | 2023 | 1656 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 7 | 2018 | 2709 | 0.180 |
Why?
|
| Neurotransmitter Agents | 3 | 2010 | 663 | 0.180 |
Why?
|
| Prognosis | 21 | 2018 | 30010 | 0.180 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 3 | 2008 | 500 | 0.180 |
Why?
|
| Personal Space | 1 | 2021 | 36 | 0.180 |
Why?
|
| Plant Extracts | 5 | 2014 | 497 | 0.180 |
Why?
|
| Acute Disease | 6 | 2018 | 7243 | 0.180 |
Why?
|
| Lipids | 5 | 2014 | 3343 | 0.180 |
Why?
|
| Mothers | 5 | 2011 | 2209 | 0.180 |
Why?
|
| Lithium Carbonate | 4 | 2004 | 179 | 0.180 |
Why?
|
| Self Disclosure | 4 | 2012 | 248 | 0.180 |
Why?
|
| Alpha Rhythm | 2 | 2020 | 112 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2018 | 702 | 0.170 |
Why?
|
| Electrocardiography | 4 | 2020 | 6412 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2011 | 2523 | 0.170 |
Why?
|
| Paranoid Behavior | 1 | 2019 | 5 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2022 | 879 | 0.170 |
Why?
|
| Menarche | 1 | 2023 | 538 | 0.170 |
Why?
|
| Overweight | 2 | 2022 | 2448 | 0.170 |
Why?
|
| Medicine | 1 | 2008 | 945 | 0.160 |
Why?
|
| Avoidance Learning | 3 | 2010 | 248 | 0.160 |
Why?
|
| Hallucinogens | 1 | 2023 | 212 | 0.160 |
Why?
|
| Hallucinations | 3 | 2022 | 373 | 0.160 |
Why?
|
| Benzophenones | 1 | 1999 | 57 | 0.160 |
Why?
|
| Thalamus | 3 | 2017 | 1047 | 0.160 |
Why?
|
| Thyrotropin-Releasing Hormone | 5 | 1993 | 139 | 0.160 |
Why?
|
| Follicular Phase | 1 | 2019 | 143 | 0.160 |
Why?
|
| Luteal Phase | 1 | 2019 | 138 | 0.160 |
Why?
|
| Nitroprusside | 1 | 2019 | 272 | 0.160 |
Why?
|
| Coronary Disease | 6 | 1996 | 5919 | 0.160 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2013 | 190 | 0.160 |
Why?
|
| Retrospective Studies | 30 | 2023 | 81762 | 0.160 |
Why?
|
| Administration, Cutaneous | 3 | 2011 | 716 | 0.160 |
Why?
|
| Purines | 6 | 2013 | 615 | 0.160 |
Why?
|
| Drug Prescriptions | 3 | 2006 | 1668 | 0.160 |
Why?
|
| Nerve Net | 3 | 2017 | 2352 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2002 | 476 | 0.160 |
Why?
|
| Translating | 2 | 2017 | 144 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 714 | 0.150 |
Why?
|
| Mother-Child Relations | 4 | 2014 | 498 | 0.150 |
Why?
|
| Longitudinal Studies | 12 | 2022 | 14783 | 0.150 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2000 | 360 | 0.150 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 2665 | 0.150 |
Why?
|
| Anorexia Nervosa | 2 | 2023 | 1364 | 0.150 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 285 | 0.150 |
Why?
|
| Child | 26 | 2023 | 80917 | 0.150 |
Why?
|
| Sexual and Gender Disorders | 1 | 1998 | 6 | 0.150 |
Why?
|
| Cerebrovascular Circulation | 2 | 2019 | 2725 | 0.150 |
Why?
|
| Autonomic Nervous System | 3 | 2018 | 707 | 0.150 |
Why?
|
| Videoconferencing | 1 | 2020 | 209 | 0.150 |
Why?
|
| Semantics | 1 | 2022 | 618 | 0.150 |
Why?
|
| Child Abuse | 2 | 2019 | 1091 | 0.150 |
Why?
|
| Globus Pallidus | 1 | 2019 | 248 | 0.150 |
Why?
|
| Personal Satisfaction | 2 | 2016 | 643 | 0.150 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 687 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 1037 | 0.150 |
Why?
|
| Cardiovascular Diseases | 5 | 2007 | 15662 | 0.150 |
Why?
|
| Breathing Exercises | 1 | 2018 | 59 | 0.150 |
Why?
|
| Phosphocreatine | 2 | 2016 | 261 | 0.140 |
Why?
|
| Brain Mapping | 7 | 2022 | 6685 | 0.140 |
Why?
|
| Learning | 3 | 2018 | 1759 | 0.140 |
Why?
|
| Referral and Consultation | 4 | 2015 | 3620 | 0.140 |
Why?
|
| Dexmedetomidine | 1 | 2022 | 320 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2024 | 1429 | 0.140 |
Why?
|
| Progesterone | 2 | 2019 | 752 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 2763 | 0.140 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2017 | 2420 | 0.140 |
Why?
|
| Benzothiazoles | 2 | 2013 | 248 | 0.140 |
Why?
|
| Serotonin Antagonists | 3 | 2018 | 147 | 0.140 |
Why?
|
| Infrared Rays | 1 | 2018 | 249 | 0.140 |
Why?
|
| Endophenotypes | 2 | 2018 | 259 | 0.140 |
Why?
|
| Inflammation | 6 | 2023 | 10873 | 0.140 |
Why?
|
| Tobacco Use Cessation | 1 | 2018 | 100 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 3706 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 3 | 2011 | 4413 | 0.140 |
Why?
|
| Social Behavior Disorders | 1 | 1997 | 100 | 0.140 |
Why?
|
| Independent Living | 2 | 2018 | 584 | 0.140 |
Why?
|
| Sexual Behavior | 4 | 2013 | 2197 | 0.140 |
Why?
|
| Association | 1 | 2016 | 53 | 0.140 |
Why?
|
| Case-Control Studies | 17 | 2022 | 22291 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2018 | 619 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 11 | 2017 | 9015 | 0.130 |
Why?
|
| Social Environment | 5 | 2012 | 1012 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2012 | 16045 | 0.130 |
Why?
|
| Sex | 1 | 1996 | 52 | 0.130 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2017 | 165 | 0.130 |
Why?
|
| Cytosol | 1 | 1999 | 887 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2004 | 951 | 0.130 |
Why?
|
| Carrier Proteins | 3 | 2010 | 4937 | 0.130 |
Why?
|
| Calcium Phosphates | 3 | 2022 | 173 | 0.130 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 59629 | 0.130 |
Why?
|
| Hypothyroidism | 3 | 2019 | 667 | 0.130 |
Why?
|
| Libido | 3 | 2013 | 124 | 0.130 |
Why?
|
| Awards and Prizes | 1 | 2020 | 365 | 0.130 |
Why?
|
| Hormones | 3 | 2023 | 866 | 0.130 |
Why?
|
| Risk-Taking | 2 | 2012 | 1023 | 0.130 |
Why?
|
| Circadian Rhythm | 3 | 2016 | 2593 | 0.130 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2008 | 326 | 0.130 |
Why?
|
| Antimetabolites | 1 | 2016 | 128 | 0.130 |
Why?
|
| Genotype | 13 | 2014 | 13045 | 0.130 |
Why?
|
| Odds Ratio | 8 | 2014 | 9669 | 0.130 |
Why?
|
| Expressed Emotion | 1 | 1996 | 92 | 0.130 |
Why?
|
| Paraquat | 1 | 2015 | 36 | 0.130 |
Why?
|
| Cycloserine | 1 | 2016 | 118 | 0.120 |
Why?
|
| Drug Interactions | 5 | 2012 | 1419 | 0.120 |
Why?
|
| Appetite | 2 | 1996 | 247 | 0.120 |
Why?
|
| Hyperthyroidism | 2 | 2010 | 292 | 0.120 |
Why?
|
| Body Weight | 4 | 2022 | 4627 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 2271 | 0.120 |
Why?
|
| Facial Expression | 2 | 2009 | 515 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2021 | 6430 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 162 | 0.120 |
Why?
|
| Swimming | 1 | 2016 | 209 | 0.120 |
Why?
|
| Telephone | 2 | 2009 | 630 | 0.120 |
Why?
|
| Health Care Surveys | 3 | 2015 | 2434 | 0.120 |
Why?
|
| Railroads | 1 | 2014 | 63 | 0.120 |
Why?
|
| Cannabis | 1 | 2021 | 446 | 0.120 |
Why?
|
| Video Games | 1 | 2017 | 202 | 0.120 |
Why?
|
| Likelihood Functions | 2 | 2011 | 994 | 0.120 |
Why?
|
| Herbicides | 1 | 2015 | 104 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 22371 | 0.120 |
Why?
|
| Organ Size | 5 | 2018 | 2267 | 0.120 |
Why?
|
| Glutamates | 1 | 2015 | 385 | 0.120 |
Why?
|
| Triazines | 1 | 2016 | 311 | 0.120 |
Why?
|
| Electronic Health Records | 4 | 2019 | 4887 | 0.110 |
Why?
|
| Program Development | 1 | 2020 | 1300 | 0.110 |
Why?
|
| Self-Assessment | 4 | 2013 | 400 | 0.110 |
Why?
|
| Algorithms | 7 | 2018 | 14164 | 0.110 |
Why?
|
| Health Surveys | 7 | 2021 | 4057 | 0.110 |
Why?
|
| Endpoint Determination | 5 | 2010 | 592 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 2337 | 0.110 |
Why?
|
| Synaptic Transmission | 1 | 2020 | 1177 | 0.110 |
Why?
|
| Drug Substitution | 2 | 2017 | 291 | 0.110 |
Why?
|
| Indoles | 2 | 2017 | 1836 | 0.110 |
Why?
|
| Accidents | 1 | 2014 | 164 | 0.110 |
Why?
|
| Thyroidectomy | 1 | 2019 | 913 | 0.110 |
Why?
|
| Psychological Techniques | 1 | 2013 | 48 | 0.110 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2017 | 533 | 0.110 |
Why?
|
| Pattern Recognition, Visual | 2 | 2010 | 826 | 0.110 |
Why?
|
| Dermatologic Agents | 1 | 2017 | 313 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2019 | 18065 | 0.110 |
Why?
|
| Diagnosis, Differential | 10 | 2017 | 13014 | 0.100 |
Why?
|
| Incidence | 9 | 2022 | 21538 | 0.100 |
Why?
|
| Radioligand Assay | 1 | 2013 | 366 | 0.100 |
Why?
|
| Phosphates | 1 | 2016 | 765 | 0.100 |
Why?
|
| Administration, Oral | 6 | 2024 | 4030 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2016 | 273 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3711 | 0.100 |
Why?
|
| Carnitine | 1 | 2014 | 253 | 0.100 |
Why?
|
| Hot Temperature | 1 | 2019 | 1441 | 0.100 |
Why?
|
| Social Stigma | 2 | 2016 | 788 | 0.100 |
Why?
|
| Taurine | 1 | 2012 | 92 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2018 | 1259 | 0.100 |
Why?
|
| International Cooperation | 2 | 2011 | 1436 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 2496 | 0.100 |
Why?
|
| Anisotropy | 4 | 2019 | 1292 | 0.100 |
Why?
|
| Histamine | 1 | 2014 | 496 | 0.100 |
Why?
|
| Thyroid Hormones | 1 | 1995 | 407 | 0.100 |
Why?
|
| Disease Progression | 8 | 2014 | 13671 | 0.100 |
Why?
|
| Medical Records | 2 | 2009 | 1410 | 0.100 |
Why?
|
| Diabetes Mellitus | 6 | 2010 | 5889 | 0.100 |
Why?
|
| Attitude of Health Personnel | 3 | 2014 | 3929 | 0.100 |
Why?
|
| Public Health | 2 | 2020 | 2679 | 0.100 |
Why?
|
| Community Mental Health Services | 1 | 2015 | 388 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2004 | 3048 | 0.100 |
Why?
|
| Central Nervous System | 1 | 2019 | 1346 | 0.100 |
Why?
|
| Cost of Illness | 5 | 2016 | 1951 | 0.100 |
Why?
|
| Agoraphobia | 2 | 2006 | 177 | 0.100 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2003 | 213 | 0.100 |
Why?
|
| Models, Neurological | 1 | 2020 | 1776 | 0.100 |
Why?
|
| Reference Values | 8 | 2017 | 4938 | 0.090 |
Why?
|
| Administrative Personnel | 1 | 1992 | 185 | 0.090 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 826 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1997 | 1243 | 0.090 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2013 | 727 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 6 | 2019 | 4640 | 0.090 |
Why?
|
| Electric Stimulation Therapy | 2 | 2015 | 635 | 0.090 |
Why?
|
| Violence | 2 | 2014 | 936 | 0.090 |
Why?
|
| Visual Cortex | 1 | 2019 | 1094 | 0.090 |
Why?
|
| Boston | 5 | 2012 | 9374 | 0.090 |
Why?
|
| Mind-Body Therapies | 1 | 2014 | 294 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 3447 | 0.090 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 556 | 0.090 |
Why?
|
| Age Distribution | 4 | 2007 | 2873 | 0.090 |
Why?
|
| Amnesia | 1 | 2013 | 257 | 0.090 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2010 | 48 | 0.090 |
Why?
|
| Hippocampus | 4 | 2019 | 3785 | 0.090 |
Why?
|
| Internal-External Control | 2 | 2010 | 348 | 0.090 |
Why?
|
| Light | 1 | 2016 | 1355 | 0.090 |
Why?
|
| Functional Laterality | 3 | 2008 | 2264 | 0.090 |
Why?
|
| Hypercholesterolemia | 3 | 2007 | 1145 | 0.090 |
Why?
|
| Dopamine Agents | 2 | 2002 | 188 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 2735 | 0.090 |
Why?
|
| New England | 4 | 2014 | 1058 | 0.090 |
Why?
|
| Corpus Striatum | 3 | 2014 | 1224 | 0.080 |
Why?
|
| Telomerase | 1 | 2015 | 751 | 0.080 |
Why?
|
| Europe | 2 | 2021 | 3436 | 0.080 |
Why?
|
| Cultural Characteristics | 2 | 2012 | 250 | 0.080 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 4 | 2012 | 300 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2016 | 2089 | 0.080 |
Why?
|
| Ventral Tegmental Area | 1 | 2010 | 135 | 0.080 |
Why?
|
| Academies and Institutes | 1 | 2012 | 326 | 0.080 |
Why?
|
| Alleles | 7 | 2011 | 6894 | 0.080 |
Why?
|
| Psoriasis | 1 | 2017 | 926 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 7454 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 411 | 0.080 |
Why?
|
| Dosage Forms | 1 | 2009 | 56 | 0.080 |
Why?
|
| Enuresis | 1 | 1989 | 50 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5536 | 0.080 |
Why?
|
| Cytokines | 3 | 2016 | 7453 | 0.080 |
Why?
|
| Executive Function | 2 | 2015 | 1401 | 0.080 |
Why?
|
| Hypertension | 3 | 2022 | 8616 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 993 | 0.080 |
Why?
|
| Biogenic Monoamines | 2 | 2016 | 50 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2010 | 346 | 0.080 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 520 | 0.080 |
Why?
|
| Thyroxine | 3 | 2014 | 665 | 0.080 |
Why?
|
| Grief | 1 | 2011 | 256 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2002 | 2732 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2017 | 2235 | 0.080 |
Why?
|
| Sex Distribution | 4 | 2013 | 2278 | 0.080 |
Why?
|
| Language | 1 | 2018 | 1557 | 0.080 |
Why?
|
| Psychology | 2 | 2008 | 353 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 1095 | 0.080 |
Why?
|
| Computer Simulation | 3 | 2022 | 6283 | 0.080 |
Why?
|
| Lepidium | 1 | 2008 | 8 | 0.080 |
Why?
|
| Acetamides | 1 | 2010 | 259 | 0.080 |
Why?
|
| Dibenzothiazepines | 1 | 2008 | 102 | 0.080 |
Why?
|
| Calcium Channels, L-Type | 1 | 2010 | 244 | 0.080 |
Why?
|
| Risk Assessment | 8 | 2019 | 24315 | 0.080 |
Why?
|
| Stereotyping | 2 | 2014 | 241 | 0.080 |
Why?
|
| Vasodilator Agents | 2 | 2003 | 990 | 0.080 |
Why?
|
| Off-Label Use | 1 | 2010 | 185 | 0.080 |
Why?
|
| Rest | 3 | 2019 | 948 | 0.070 |
Why?
|
| Signal Detection, Psychological | 1 | 2008 | 84 | 0.070 |
Why?
|
| Genome-Wide Association Study | 5 | 2022 | 12795 | 0.070 |
Why?
|
| Huntington Disease | 2 | 2010 | 1147 | 0.070 |
Why?
|
| Feedback | 1 | 2012 | 799 | 0.070 |
Why?
|
| Control Groups | 1 | 2008 | 107 | 0.070 |
Why?
|
| Sickness Impact Profile | 2 | 2012 | 299 | 0.070 |
Why?
|
| Endocrine System Diseases | 1 | 2010 | 250 | 0.070 |
Why?
|
| Random Allocation | 3 | 2019 | 2396 | 0.070 |
Why?
|
| Models, Theoretical | 2 | 2017 | 3573 | 0.070 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2000 | 119 | 0.070 |
Why?
|
| Sample Size | 4 | 2020 | 846 | 0.070 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2008 | 57 | 0.070 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2007 | 44 | 0.070 |
Why?
|
| Consensus | 1 | 2017 | 3212 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2011 | 779 | 0.070 |
Why?
|
| Succinylcholine | 1 | 2007 | 67 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 354 | 0.070 |
Why?
|
| Receptors, AMPA | 1 | 2009 | 334 | 0.070 |
Why?
|
| Patient Satisfaction | 5 | 2016 | 3488 | 0.070 |
Why?
|
| Insurance, Psychiatric | 1 | 2007 | 66 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3728 | 0.070 |
Why?
|
| Decision Trees | 3 | 2007 | 508 | 0.070 |
Why?
|
| Perceptual Distortion | 1 | 2007 | 36 | 0.070 |
Why?
|
| Constipation | 1 | 2012 | 570 | 0.070 |
Why?
|
| Spin Labels | 2 | 2019 | 336 | 0.070 |
Why?
|
| Tranylcypromine | 1 | 2006 | 30 | 0.070 |
Why?
|
| Wounds and Injuries | 2 | 2018 | 2517 | 0.070 |
Why?
|
| International Classification of Diseases | 2 | 2011 | 937 | 0.070 |
Why?
|
| Least-Squares Analysis | 2 | 2004 | 367 | 0.070 |
Why?
|
| ROC Curve | 3 | 2011 | 3628 | 0.070 |
Why?
|
| Uremia | 1 | 1988 | 202 | 0.070 |
Why?
|
| Relaxation Therapy | 1 | 2008 | 181 | 0.070 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2007 | 118 | 0.070 |
Why?
|
| Conduct Disorder | 1 | 2008 | 245 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 1119 | 0.070 |
Why?
|
| Data Collection | 4 | 2007 | 3327 | 0.070 |
Why?
|
| Counseling | 1 | 2014 | 1554 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 1209 | 0.070 |
Why?
|
| Family Relations | 1 | 2008 | 318 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2018 | 3467 | 0.070 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2006 | 64 | 0.060 |
Why?
|
| Withholding Treatment | 2 | 2008 | 620 | 0.060 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 159 | 0.060 |
Why?
|
| Waist Circumference | 1 | 2009 | 935 | 0.060 |
Why?
|
| Animals | 9 | 2022 | 169246 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 2009 | 2923 | 0.060 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2005 | 18 | 0.060 |
Why?
|
| Dominance, Cerebral | 4 | 2008 | 623 | 0.060 |
Why?
|
| Glutamic Acid | 1 | 2011 | 1191 | 0.060 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2005 | 36 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 458 | 0.060 |
Why?
|
| Speech Recognition Software | 1 | 2005 | 74 | 0.060 |
Why?
|
| Interleukin-6 | 3 | 2022 | 3228 | 0.060 |
Why?
|
| Amenorrhea | 1 | 1989 | 484 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2815 | 0.060 |
Why?
|
| Military Personnel | 2 | 1993 | 1261 | 0.060 |
Why?
|
| Empirical Research | 1 | 2005 | 119 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 2048 | 0.060 |
Why?
|
| Minority Groups | 1 | 2012 | 1216 | 0.060 |
Why?
|
| Patients | 1 | 2011 | 908 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1196 | 0.060 |
Why?
|
| Inositol | 2 | 2010 | 216 | 0.060 |
Why?
|
| Nervous System | 1 | 2008 | 544 | 0.060 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2006 | 277 | 0.060 |
Why?
|
| Lung Diseases | 1 | 1995 | 1944 | 0.060 |
Why?
|
| Cerebral Ventricles | 1 | 2007 | 550 | 0.060 |
Why?
|
| Posterior Cerebral Artery | 1 | 2024 | 35 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2008 | 958 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 14729 | 0.060 |
Why?
|
| Psychophysiology | 1 | 2004 | 137 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 3556 | 0.060 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2004 | 42 | 0.060 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 771 | 0.060 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2024 | 82 | 0.060 |
Why?
|
| Software | 2 | 2015 | 4478 | 0.060 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2023 | 49 | 0.060 |
Why?
|
| Benzazepines | 1 | 2006 | 308 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 4 | 2010 | 1206 | 0.050 |
Why?
|
| Phenotype | 7 | 2010 | 16726 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 2784 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 1627 | 0.050 |
Why?
|
| Drug Approval | 1 | 2010 | 821 | 0.050 |
Why?
|
| Verbal Behavior | 1 | 2004 | 336 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2019 | 2596 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2015 | 3968 | 0.050 |
Why?
|
| Acculturation | 2 | 2016 | 179 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 2258 | 0.050 |
Why?
|
| Middle Cerebral Artery | 1 | 2024 | 271 | 0.050 |
Why?
|
| Mental Health | 2 | 2014 | 3275 | 0.050 |
Why?
|
| Attention | 2 | 2010 | 2424 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2018 | 4852 | 0.050 |
Why?
|
| Social Support | 2 | 2014 | 2193 | 0.050 |
Why?
|
| Forecasting | 3 | 2017 | 2945 | 0.050 |
Why?
|
| Safety | 1 | 2007 | 1159 | 0.050 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2013 | 1481 | 0.050 |
Why?
|
| Sleep Stages | 1 | 2006 | 706 | 0.050 |
Why?
|
| Dextromethorphan | 1 | 2022 | 37 | 0.050 |
Why?
|
| Self Care | 1 | 2008 | 799 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 1397 | 0.050 |
Why?
|
| Parenting | 1 | 2008 | 708 | 0.050 |
Why?
|
| Raclopride | 1 | 2022 | 102 | 0.050 |
Why?
|
| Postpartum Period | 2 | 2022 | 1198 | 0.050 |
Why?
|
| Administration, Sublingual | 1 | 2022 | 60 | 0.050 |
Why?
|
| Clomipramine | 2 | 1993 | 50 | 0.050 |
Why?
|
| Time | 1 | 2004 | 552 | 0.050 |
Why?
|
| Eating | 1 | 2008 | 1542 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 2538 | 0.050 |
Why?
|
| Adiponectin | 2 | 2019 | 1117 | 0.050 |
Why?
|
| Adenosine Triphosphate | 3 | 2008 | 2004 | 0.050 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2022 | 107 | 0.050 |
Why?
|
| Inpatients | 1 | 2013 | 2566 | 0.050 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2002 | 170 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 12252 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2008 | 2603 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2007 | 840 | 0.050 |
Why?
|
| Achievement | 1 | 2003 | 288 | 0.050 |
Why?
|
| Nausea | 1 | 2004 | 682 | 0.050 |
Why?
|
| Dizziness | 1 | 2004 | 269 | 0.050 |
Why?
|
| Family Health | 1 | 2006 | 1255 | 0.050 |
Why?
|
| Ghrelin | 1 | 2023 | 251 | 0.050 |
Why?
|
| Neuronal Plasticity | 2 | 2022 | 1448 | 0.050 |
Why?
|
| Health Behavior | 1 | 1992 | 2650 | 0.050 |
Why?
|
| Risk Management | 1 | 2004 | 558 | 0.050 |
Why?
|
| Canada | 2 | 2020 | 2130 | 0.050 |
Why?
|
| Health Promotion | 1 | 2013 | 2210 | 0.050 |
Why?
|
| Social Perception | 1 | 2004 | 434 | 0.050 |
Why?
|
| Retreatment | 3 | 2008 | 598 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 1500 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 1904 | 0.050 |
Why?
|
| Alcoholics Anonymous | 1 | 2020 | 32 | 0.050 |
Why?
|
| Maintenance | 1 | 2020 | 25 | 0.040 |
Why?
|
| Perception | 2 | 2021 | 1209 | 0.040 |
Why?
|
| Principal Component Analysis | 2 | 2017 | 948 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2024 | 1104 | 0.040 |
Why?
|
| Anemia, Macrocytic | 1 | 2000 | 53 | 0.040 |
Why?
|
| Health Personnel | 3 | 2021 | 3385 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2018 | 1489 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 94 | 0.040 |
Why?
|
| Pindolol | 1 | 2000 | 34 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2008 | 1812 | 0.040 |
Why?
|
| GABA Modulators | 1 | 2020 | 109 | 0.040 |
Why?
|
| Sleep Arousal Disorders | 1 | 1999 | 12 | 0.040 |
Why?
|
| Creatinine | 1 | 2005 | 1918 | 0.040 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 12543 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 1485 | 0.040 |
Why?
|
| Epidemiologic Research Design | 1 | 2003 | 368 | 0.040 |
Why?
|
| Social Isolation | 1 | 2002 | 366 | 0.040 |
Why?
|
| California | 1 | 2004 | 1438 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 5176 | 0.040 |
Why?
|
| Program Evaluation | 3 | 2015 | 2507 | 0.040 |
Why?
|
| Schizophrenic Psychology | 2 | 2016 | 1649 | 0.040 |
Why?
|
| Italy | 2 | 2010 | 856 | 0.040 |
Why?
|
| Drug Monitoring | 3 | 2013 | 964 | 0.040 |
Why?
|
| Individuality | 1 | 2021 | 307 | 0.040 |
Why?
|
| Raphe Nuclei | 1 | 2019 | 104 | 0.040 |
Why?
|
| Nitrophenols | 1 | 1999 | 169 | 0.040 |
Why?
|
| Interpersonal Relations | 2 | 2004 | 1434 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2008 | 2907 | 0.040 |
Why?
|
| Methionine | 2 | 2012 | 573 | 0.040 |
Why?
|
| Vasopressins | 1 | 2020 | 358 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2021 | 613 | 0.040 |
Why?
|
| Phosphorus | 2 | 2016 | 336 | 0.040 |
Why?
|
| Headache | 1 | 2006 | 1263 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2002 | 496 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 1988 | 1791 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2009 | 6526 | 0.040 |
Why?
|
| Behavior | 1 | 2001 | 542 | 0.040 |
Why?
|
| Aftercare | 1 | 2024 | 916 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2007 | 1388 | 0.040 |
Why?
|
| North America | 1 | 2021 | 1289 | 0.040 |
Why?
|
| Pandemics | 3 | 2022 | 8748 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 22379 | 0.040 |
Why?
|
| Prescriptions | 1 | 2020 | 388 | 0.040 |
Why?
|
| Pregnancy | 4 | 2023 | 30256 | 0.040 |
Why?
|
| Dexamethasone | 4 | 2010 | 1965 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2007 | 1516 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2004 | 1835 | 0.030 |
Why?
|
| Professional Competence | 1 | 2000 | 430 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2019 | 15832 | 0.030 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2009 | 108 | 0.030 |
Why?
|
| Adrenal Medulla | 1 | 2016 | 56 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 70 | 0.030 |
Why?
|
| Gene Frequency | 3 | 2010 | 3623 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2020 | 1090 | 0.030 |
Why?
|
| Physicians | 1 | 2014 | 4598 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2004 | 1200 | 0.030 |
Why?
|
| Nucleosides | 1 | 1997 | 130 | 0.030 |
Why?
|
| Rats | 1 | 2012 | 23760 | 0.030 |
Why?
|
| Adrenal Cortex | 1 | 2016 | 134 | 0.030 |
Why?
|
| Stroke | 1 | 2018 | 9755 | 0.030 |
Why?
|
| Blood Pressure | 3 | 2021 | 8543 | 0.030 |
Why?
|
| Clozapine | 1 | 2019 | 509 | 0.030 |
Why?
|
| Color | 1 | 2016 | 296 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2011 | 3463 | 0.030 |
Why?
|
| Decision Making | 1 | 2009 | 3953 | 0.030 |
Why?
|
| New South Wales | 1 | 2015 | 69 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2007 | 1946 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 1854 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2000 | 10101 | 0.030 |
Why?
|
| Cell Communication | 1 | 2022 | 1660 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2017 | 563 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 1995 | 396 | 0.030 |
Why?
|
| Methylation | 1 | 2018 | 1078 | 0.030 |
Why?
|
| Embolism | 1 | 2018 | 401 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2007 | 2420 | 0.030 |
Why?
|
| Amino Acids | 1 | 2001 | 1716 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2015 | 222 | 0.030 |
Why?
|
| Anticipation, Psychological | 1 | 2015 | 91 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2015 | 177 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 1995 | 289 | 0.030 |
Why?
|
| Amitriptyline | 1 | 2014 | 112 | 0.030 |
Why?
|
| Binding Sites | 1 | 2002 | 6020 | 0.030 |
Why?
|
| Rage | 1 | 1993 | 29 | 0.030 |
Why?
|
| Motor Activity | 2 | 2015 | 2711 | 0.030 |
Why?
|
| Sex Offenses | 1 | 2018 | 357 | 0.030 |
Why?
|
| Dementia | 1 | 2009 | 2740 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 857 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2015 | 615 | 0.030 |
Why?
|
| Syndrome | 2 | 2006 | 3272 | 0.030 |
Why?
|
| Medicaid | 1 | 2007 | 2840 | 0.030 |
Why?
|
| Body Temperature | 1 | 2016 | 780 | 0.030 |
Why?
|
| Psychology, Comparative | 1 | 2013 | 6 | 0.030 |
Why?
|
| Punishment | 1 | 2014 | 95 | 0.030 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 5367 | 0.030 |
Why?
|
| Psychiatric Department, Hospital | 2 | 2007 | 133 | 0.030 |
Why?
|
| England | 1 | 2014 | 533 | 0.030 |
Why?
|
| Auditory Cortex | 1 | 2017 | 363 | 0.030 |
Why?
|
| Tomography | 1 | 2015 | 442 | 0.030 |
Why?
|
| Awareness | 1 | 1997 | 654 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 392 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2017 | 1255 | 0.020 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2013 | 103 | 0.020 |
Why?
|
| Dichotic Listening Tests | 1 | 1991 | 22 | 0.020 |
Why?
|
| Caffeine | 1 | 1996 | 703 | 0.020 |
Why?
|
| Classification | 1 | 2012 | 128 | 0.020 |
Why?
|
| Exercise | 1 | 2008 | 5955 | 0.020 |
Why?
|
| Acupuncture Points | 1 | 2012 | 111 | 0.020 |
Why?
|
| Triglycerides | 2 | 2014 | 2464 | 0.020 |
Why?
|
| Biological Availability | 1 | 2012 | 389 | 0.020 |
Why?
|
| Psychophysiologic Disorders | 1 | 1993 | 223 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1996 | 785 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1793 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 1992 | 305 | 0.020 |
Why?
|
| Hypothalamus | 1 | 2016 | 1004 | 0.020 |
Why?
|
| Insurance | 1 | 1992 | 115 | 0.020 |
Why?
|
| Financial Management | 1 | 1992 | 161 | 0.020 |
Why?
|
| Leisure Activities | 1 | 1992 | 310 | 0.020 |
Why?
|
| Rhodiola | 1 | 2010 | 3 | 0.020 |
Why?
|
| Medial Forebrain Bundle | 1 | 2010 | 42 | 0.020 |
Why?
|
| 5-Hydroxytryptophan | 1 | 2010 | 33 | 0.020 |
Why?
|
| Government Regulation | 1 | 2015 | 525 | 0.020 |
Why?
|
| MEDLINE | 1 | 2010 | 119 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1993 | 241 | 0.020 |
Why?
|
| Water | 1 | 2017 | 1421 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 958 | 0.020 |
Why?
|
| Stroop Test | 1 | 2010 | 72 | 0.020 |
Why?
|
| Adrenomedullin | 1 | 2010 | 85 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3269 | 0.020 |
Why?
|
| Beauty | 1 | 2010 | 41 | 0.020 |
Why?
|
| Herbal Medicine | 1 | 2010 | 37 | 0.020 |
Why?
|
| Ethanol | 1 | 1996 | 1331 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2022 | 42669 | 0.020 |
Why?
|
| Primidone | 1 | 2009 | 9 | 0.020 |
Why?
|
| Addison Disease | 1 | 2010 | 48 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1992 | 1377 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2017 | 2937 | 0.020 |
Why?
|
| Cerebellum | 1 | 1997 | 1522 | 0.020 |
Why?
|
| Receptors, Vasopressin | 1 | 2010 | 106 | 0.020 |
Why?
|
| Warfarin | 1 | 2018 | 1493 | 0.020 |
Why?
|
| Leukocytes | 1 | 2018 | 2035 | 0.020 |
Why?
|
| Eligibility Determination | 1 | 2013 | 421 | 0.020 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2010 | 88 | 0.020 |
Why?
|
| Chromium | 1 | 2010 | 133 | 0.020 |
Why?
|
| Educational Status | 2 | 2007 | 2515 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2002 | 2819 | 0.020 |
Why?
|
| Quinazolines | 1 | 2016 | 1373 | 0.020 |
Why?
|
| Paternal Deprivation | 1 | 1989 | 10 | 0.020 |
Why?
|
| Galactorrhea | 1 | 1989 | 23 | 0.020 |
Why?
|
| Alprazolam | 1 | 1989 | 103 | 0.020 |
Why?
|
| Manuals as Topic | 1 | 1989 | 99 | 0.020 |
Why?
|
| Cost Savings | 1 | 2014 | 904 | 0.020 |
Why?
|
| Medicare | 1 | 2007 | 6809 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2018 | 3390 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2010 | 361 | 0.020 |
Why?
|
| Visual Perception | 1 | 2016 | 1402 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2017 | 4146 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2010 | 781 | 0.020 |
Why?
|
| Single Person | 1 | 2007 | 31 | 0.020 |
Why?
|
| Risk | 2 | 2014 | 9613 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2011 | 412 | 0.020 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2010 | 180 | 0.020 |
Why?
|
| Plant Roots | 1 | 2008 | 122 | 0.020 |
Why?
|
| Occipital Lobe | 1 | 2009 | 376 | 0.020 |
Why?
|
| Oxygen | 2 | 2009 | 4270 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 1820 | 0.020 |
Why?
|
| Guilt | 1 | 2007 | 93 | 0.020 |
Why?
|
| Phototherapy | 1 | 2010 | 368 | 0.020 |
Why?
|
| Aging | 1 | 2006 | 8744 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2007 | 5953 | 0.020 |
Why?
|
| Parents | 1 | 2021 | 3595 | 0.020 |
Why?
|
| Meditation | 1 | 2010 | 257 | 0.020 |
Why?
|
| Speech Perception | 1 | 1991 | 510 | 0.020 |
Why?
|
| Rodentia | 1 | 2008 | 262 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2008 | 307 | 0.020 |
Why?
|
| Estradiol | 1 | 2013 | 1951 | 0.020 |
Why?
|
| Propensity Score | 1 | 2014 | 1969 | 0.020 |
Why?
|
| Genes | 1 | 2010 | 1824 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2010 | 797 | 0.020 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2010 | 383 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 1260 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 285 | 0.020 |
Why?
|
| Texas | 1 | 2006 | 410 | 0.020 |
Why?
|
| Progestins | 1 | 2007 | 302 | 0.020 |
Why?
|
| Food | 1 | 2010 | 768 | 0.020 |
Why?
|
| Patient Preference | 1 | 2013 | 946 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2006 | 169 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2010 | 2342 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2007 | 359 | 0.010 |
Why?
|
| Crime | 1 | 2006 | 206 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1992 | 2003 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2006 | 567 | 0.010 |
Why?
|
| Exploratory Behavior | 1 | 2005 | 272 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 2403 | 0.010 |
Why?
|
| Magnesium | 1 | 2008 | 815 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1143 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3833 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2015 | 3140 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 4352 | 0.010 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2006 | 305 | 0.010 |
Why?
|
| Protons | 1 | 2009 | 1113 | 0.010 |
Why?
|
| Vagus Nerve | 1 | 2006 | 459 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 2010 | 1997 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2014 | 2479 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2018 | 4428 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2008 | 1997 | 0.010 |
Why?
|
| Causality | 1 | 2009 | 1254 | 0.010 |
Why?
|
| Chemokines | 1 | 2007 | 963 | 0.010 |
Why?
|
| Diet | 1 | 2001 | 8089 | 0.010 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2002 | 20 | 0.010 |
Why?
|
| Life Style | 2 | 1993 | 3932 | 0.010 |
Why?
|
| Orgasm | 1 | 2002 | 62 | 0.010 |
Why?
|
| Checklist | 1 | 2009 | 840 | 0.010 |
Why?
|
| Natural Language Processing | 1 | 2011 | 1203 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 4620 | 0.010 |
Why?
|
| Thionucleotides | 1 | 2001 | 107 | 0.010 |
Why?
|
| Memory, Short-Term | 1 | 2008 | 1008 | 0.010 |
Why?
|
| Epilepsy | 1 | 1997 | 3327 | 0.010 |
Why?
|
| Environment | 1 | 2007 | 1121 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2017 | 3803 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2722 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2014 | 3591 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2014 | 3239 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2007 | 1320 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 6082 | 0.010 |
Why?
|
| Memory | 1 | 2010 | 2208 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2010 | 2744 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2008 | 2766 | 0.010 |
Why?
|
| Physician's Role | 1 | 2007 | 925 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 2000 | 157 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2008 | 1892 | 0.010 |
Why?
|
| Cause of Death | 1 | 2010 | 3721 | 0.010 |
Why?
|
| Pedigree | 1 | 2007 | 4539 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 3415 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 4120 | 0.010 |
Why?
|
| Mortality | 1 | 2010 | 2911 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2000 | 365 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2007 | 1135 | 0.010 |
Why?
|
| Personality | 1 | 2001 | 559 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2013 | 8080 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2003 | 905 | 0.010 |
Why?
|
| Half-Life | 1 | 1998 | 651 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2007 | 2118 | 0.010 |
Why?
|
| Histrionic Personality Disorder | 1 | 1996 | 10 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 3447 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 5797 | 0.010 |
Why?
|
| Cephalometry | 1 | 1997 | 380 | 0.010 |
Why?
|
| Health Services Research | 1 | 2003 | 1815 | 0.010 |
Why?
|
| Compulsive Personality Disorder | 1 | 1995 | 48 | 0.010 |
Why?
|
| Narcissism | 1 | 1995 | 59 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23645 | 0.010 |
Why?
|
| Antisocial Personality Disorder | 1 | 1995 | 224 | 0.010 |
Why?
|
| Curriculum | 1 | 2007 | 3782 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 7608 | 0.010 |
Why?
|
| Fluorine | 1 | 1992 | 83 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 2486 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 5520 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2007 | 4858 | 0.010 |
Why?
|
| Infant | 1 | 2013 | 36535 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2010 | 12168 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 11928 | 0.010 |
Why?
|
| Communication | 1 | 2004 | 3905 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1993 | 891 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 12077 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1993 | 1609 | 0.000 |
Why?
|
| Hospitalization | 1 | 1999 | 10840 | 0.000 |
Why?
|